Natalizumab Antibodies
Also known as: NATAL ABS
Use
This test aids in the management of individuals receiving natalizumab therapy. Natalizumab is an immunosuppressive drug used to treat some chronic inflammatory conditions. Detecting antibodies to natalizumab can be important for evaluating treatment effectiveness and monitoring for drug-related adverse reactions such as the development of neutralizing antibodies which may diminish the efficacy of the treatment.
Special Instructions
This test is not performed at ARUP Laboratories; separate specimens must be submitted when multiple tests are ordered. Ensure proper specimen handling by allowing blood to clot at room temperature for 30 minutes before serum separation.
Limitations
The test was developed and its performance characteristics were determined by Eurofins Viracor, but it has not been cleared or approved by the U.S. Food and Drug Administration. Potential limitations include false positives or negatives due to cross-reactivity or insufficient sensitivity to detect low antibody levels.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 58012-6
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Allow blood to clot at room temperature for 30 minutes. Separate serum from cells within 1 hour.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 2 Weeks |
| Frozen | 2 Weeks |